ESI-GROUP/JMDA-DESIGN
22.10.2020 09:02:04 CEST | Business Wire | Press release
With a relationship that spans more than a decade, JMDA Design and ESI Group (Paris:ESI) worked together on the Tinyseats child car seat project which resulted in the highly acclaimed Red Dot Award: Design Concept 2020.
Multi-award winning JMDA Design has collaborated with ESI Group, a global player in virtual prototyping software and services for industrials, for many years. Their unique partnership enabled the Tinyseats child car seat project from Tinyseats Europe AB to undergo rigorous testing without the need of any physical prototypes. They were able to do this at the early stages of development to gain additional information about product performance and to help de-risk compliance challenges in a test situation. Using Virtual Prototyping by working with ESI Group, particularly for innovative, cutting-edge child restraint systems (CRS), ensures dynamic performance is optimised with controlled time and investment, from the upstream phases of the product design process.
Derrick Barker, Founder and Director at JMDA explains, “The Red Dot Award: Design Concept 2020 for the Tinyseats child car seat was a ground-breaking project aiming to achieve a very lightweight, compact and convertible car seat for children from 9 months old. Working with ESI Group enabled JMDA to gain substantial insight into the performance of the car seat early on in the design process, especially the load bearing structure, which could be fully evaluated in a virtual environment.” Derrick adds, “As our relationship goes from strength to strength with ESI Group we are backed by a team sharing our passion for innovation with the highest safety standards”.
“We are really proud to be part of JMDA journey for many years now. Their commitment toward safety and comfort compelled with their undisputed design expertise make them a key player in the car seat industry. Helping industrials to commit to such outcome is truly embarked in our DNA and our strategy. This Red Do Award proves that allowing any compromise between, design, safety and performance is possible with the appropriate expertise, solutions and trust-based relationship .” declares Jonas Fredriksson, Managing Director – ESI Northern Europe
JMDA Design, a global provider for product design services with nearly 30 years’ experience in the industry, is currently designing their 105th child car seat, have. Partnering with world leading specialists, like ESI Group, is a critical part of ensuring a truly holistic approach to innovative product design.
About ESI
Founded in 1973, ESI Group is a leading innovator in Virtual Prototyping solutions and a global enabler of industrial transformation. Thanks to the company’s unique know-how in the physics of materials, it has developed and refined, over the last 45 years, advanced simulation capabilities. Having identified gaps in the traditional approach to Product Lifecycle Management (PLM), ESI has introduced a holistic methodology centered on industrial productivity and product performance throughout its entire lifecycle, i.e. Product Performance Lifecycle™, from engineering to manufacturing and in operation.
Present in more than 20 countries, and in major industrial sectors, ESI employs 1200 high level specialists. In 2019, its proforma turnover was 146.2M€. ESI is headquartered in France and is listed on compartment B of Euronext Paris.
For further information, go to www.esi-group.com .
For more information about the partnership between JMDA Design and ESI Group, please give Derrick Barker a call on +44 (0) 1386 426100 or email derrick.barker@jmda.co.uk .
- ENDS -
Notes to Editor
- JMDA Design specialise in the design and development of a diverse range of products including child car seats, stair lifts, showers, smoke alarms and highchairs.
- JMDA Design have two offices one in Pershore, Worcestershire and one in Shanghai, China.
- They support clients across the world with testing, manufacturing and distribution of the products they design.
- Awards for innovation and international activity include:
2020 – Winners of Red Dot Award: Design Concept 2020
2019 - Winners of The Queen’s Awards for Enterprise: International Trade 2019
2019 – Winners of a German Design Award 2020
2018 – International Design Award Winners
2017 - Highly Commended ‘Exporter of the Year’ - Hereford and Worcestershire Chamber of Commerce Awards
2016 – Winners of Red Dot Award: Design Concept 2016
2014 – Winner of the Progressive Preschool Innovation Award (Flippa Folding Dining Booster)
2012 – Finalist of the Hereford and Worcestershire Chamber of Commerce International Business Award
2010 – Winner of the International Business of the Year Award
2009 – Finalist of the Kind & Jugend Innovation Award
2008 – Finalist of the Kind & Jugend Innovation Award
2008 – Finalist of the Chamber of Commerce Small Business of the Year Award
View source version on businesswire.com: https://www.businesswire.com/news/home/20201022005088/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
